MedCity News

Why Hospitals Must Rethink Operations Before Banking on AI

Why Employers Think the 340B Program Needs Reform

Employers are advocating for changes to the 340B Drug Pricing Program, arguing that it allows hospitals to "buy low and sell high" by purchasing discounted medications and charging insured patients full price.

By Marissa Plescia

BioPharma

BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal

Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema.

By Frank Vinluan

MedCity Influencers

No Wrong Door: How Policy, Technology & Partnerships Can Power a Connected Social Safety Net

Through the convergence of proactive policy, advanced technology and strategic public-private partnerships, we can achieve this “no wrong door” vision and deliver a connected, streamlined social safety net that’s more efficient, economical, and effective. Here’s how.

By Carla Nelson

Latest News

Startups, Health Tech, Artificial Intelligence Diagnostics,

EnsoData Snags $20M to Improve Sleep Disorder Diagnostics

EnsoData raised $20 million in Series B funds for its AI-powered sleep diagnostics. The company’s technology aims to help clinicians diagnose sleep disorders faster and more consistently.

By Katie Adams

BioPharma, Pharma

Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease

Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said.

By Frank Vinluan

Solving Healthcare’s Provider Data Problem Starts with Interoperability

Break down the silos. Take control of your provider data.

By ProviderTrust

MedCity Influencers

How More Competition and Better Connected Data Will Solve Healthcare’s Trillion Dollar Problem

There are two changes that could transform the entire system. If we can do these two things, the entire market improves. Not everyone will win, but the good products, the good distributors and the good platforms will rise to the top.

By Sina Chehrazi

MedCity Influencers

A Father’s Promise: Breaking the Cycle of Trauma and Addiction for My Son

To any father that's struggling right now, know this: your past doesn’t have to write your future. Help is out there, and you can change the trajectory of your life and that of your family.

By Mike Diamond

Hospitals, Health Tech Artificial Intelligence,

The Hospital Word Has Become a Tale of the Haves and Have-Nots

Health system performance has splintered into three distinct groups — leaders, strugglers and those stuck in the middle, according to Fitch Ratings’ Kevin Holloran. At the HFMA Annual Conference, he and Mayo Clinic CFO Dennis Dahlen discussed how technology and innovation are accelerating this divide.

By Katie Adams

Health Tech, Consumer / Employer

Why Novo Nordisk Is Dropping Its Collaboration with Hims & Hers

Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.

By Marissa Plescia

BioPharma, Pharma

Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear

Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis.

By Frank Vinluan

MedCity Influencers

How Smarter Metrics Can Unlock AI’s Potential in Healthcare

Healthcare doesn’t reward shortcuts. It rewards outcomes. AI will play a critical role in shaping those outcomes — but only if leaders measure what truly matters. The best AI implementations elevate expertise, improve quality and create space for innovation.

By Updesh Dosanjh

MedCity Influencers

What the New CMS Strategy Signals for Rehab Professionals

The CMS vision is ambitious, but so is the potential for rehab therapy to shape its execution. To do that, providers must actively engage, document their impact, and advocate for their inclusion in evolving models of care.

By Susan Lofton

Payers

More Than 50 Health Plans Commit to Simplifying Prior Authorization

Several insurers, such as UnitedHealthcare, Aetna and Cigna, pledged to improve prior authorization. These changes include streamlining decision timelines and increasing transparency.

By Marissa Plescia

Health Tech, Artificial Intelligence Providers,

Why This Former OpenAI Exec Is Urging Health Leaders to ‘Specialize in Empathy’

At the HFMA Annual Conference, AI expert Zack Kass shared a personal story to emphasize the enduring importance of human qualities like empathy and compassion in healthcare. In his view, these qualities will only become more essential as AI continues to transform the clinical landscape.

By Katie Adams

BioPharma, Pharma

Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence

In Phase 1/2 results for 12 patients at least one year after receiving the cell therapy, zimislecel, Vertex Pharmaceuticals reported all participants achieved blood glucose in the target range and 10 of the 12 were free of exogenous insulin as of the data cutoff. Vertex expects to complete enrollment in the pivotal portion of the study this summer, paving the way for potential regulatory submissions next year.

By Frank Vinluan